Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us
Summary
GlobalData has released its new PharmaPoint Country Evaluation report, PharmaPoint: Colorectal Cancer - Japan Drug Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems.
To Browse a Full Report with Toc: http://www.researchmoz.us/pharmapoint-colorectal-cancer-japan-drug-forecast-and-market-analysis-to-2023-report.html
This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Avastin (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin and Vectibix are not recommended.
Scope
- Overview of CRC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the Japan CRC market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for CRC
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in Japan.
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 16
3.2 Clinical Staging 17
3.3 Symptoms 19
4 Disease Management 20
4.1 Diagnosis and Treatment Overview 20
4.1.1 Screening and Diagnosis 20
1.1 List of Tables
Table 1: TNM and Staging Classification System for CRC 18
Table 2: Symptoms of Colorectal Cancer 19
Table 3: Treatment Guidelines for CRC 23
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the US Markets, 2013 24
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the US Markets, 2013 24
Table 6: Country Profile - Japan 31
Table 7: Leading Treatments for CRC, 2014 35
Table 8: Product Profile Avastin 37
Table 9: Avastin SWOT Analysis, 2014 39
Table 10: Product Profile Erbitux 41
Table 11: Erbitux SWOT Analysis, 2014 43
Table 12: Product Profile - Vectibix 45
Table 13: Vectibix SWOT Analysis, 2014 46
Table 14: Product Profile - Stivarga 49
Table 15: Stivarga SWOT Analysis, 2014 50
To Browse a Full Report with Toc: http://www.researchmoz.us/pharmapoint-colorectal-cancer-japan-drug-forecast-and-market-analysis-to-2023-report.html
All Reports of this Category Here: http://www.researchmoz.us/pharmaceutical-market-reports-38.html
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact US:
For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463
Summary
GlobalData has released its new PharmaPoint Country Evaluation report, PharmaPoint: Colorectal Cancer - Japan Drug Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems.
To Browse a Full Report with Toc: http://www.researchmoz.us/pharmapoint-colorectal-cancer-japan-drug-forecast-and-market-analysis-to-2023-report.html
This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Avastin (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin and Vectibix are not recommended.
Scope
- Overview of CRC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the Japan CRC market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for CRC
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in Japan.
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 16
3.2 Clinical Staging 17
3.3 Symptoms 19
4 Disease Management 20
4.1 Diagnosis and Treatment Overview 20
4.1.1 Screening and Diagnosis 20
1.1 List of Tables
Table 1: TNM and Staging Classification System for CRC 18
Table 2: Symptoms of Colorectal Cancer 19
Table 3: Treatment Guidelines for CRC 23
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the US Markets, 2013 24
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the US Markets, 2013 24
Table 6: Country Profile - Japan 31
Table 7: Leading Treatments for CRC, 2014 35
Table 8: Product Profile Avastin 37
Table 9: Avastin SWOT Analysis, 2014 39
Table 10: Product Profile Erbitux 41
Table 11: Erbitux SWOT Analysis, 2014 43
Table 12: Product Profile - Vectibix 45
Table 13: Vectibix SWOT Analysis, 2014 46
Table 14: Product Profile - Stivarga 49
Table 15: Stivarga SWOT Analysis, 2014 50
To Browse a Full Report with Toc: http://www.researchmoz.us/pharmapoint-colorectal-cancer-japan-drug-forecast-and-market-analysis-to-2023-report.html
All Reports of this Category Here: http://www.researchmoz.us/pharmaceutical-market-reports-38.html
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact US:
For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463
No comments:
Post a Comment